Reference

1. Rajapakse D, Liossi C, Howard RF. Presentation and management of chronic pain. Archives of Disease in Childhood. 2014;99(5):474–80. doi:10.1136/archdischild-2013-304207
2. Nijs J, George SZ, Clauw DJ, Fernández-de-las-Peñas C, Kosek E, Ickmans K, et al. Central sensitisation in chronic pain conditions: Latest discoveries and their potential for precision medicine. The Lancet Rheumatology. 2021;3(5). doi:10.1016/s2665-9913(21)00032-1
3. Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: A Review. Current Psychiatry Reports. 2016;18(2). doi:10.1007/s11920-015-0659-9
4. 4.Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77–92. doi:10.1016/j.neuron.2006.09.021
5. Puntillo F, Giglio M, Paladini A, Perchiazzi G, Viswanath O, Urits I, et al. Pathophysiology of musculoskeletal pain: A narrative review. Therapeutic Advances in Musculoskeletal Disease. 2021;13. doi:10.1177/1759720x21995067
6. Chen L, Yang G, Grosser T. Prostanoids and Inflammatory Pain. Prostaglandins & Other Lipid Mediators. 2013;104–105:58–66. doi:10.1016/j.prostaglandins.2012.08.006
7. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O’Brien T, Mercadante S, et al. Standards for the management of cancer?related pain across Europe—a position paper from the EFIC Task Force on Cancer Pain. European Journal of Pain. 2019;23(4):660–8. doi:10.1002/ejp.1346
8. Vallerand AH, Templin T, Hasenau SM, Riley-Doucet C. Factors that affect functional status in patients with cancer-related pain. Pain. 2007;132(1):82–90. doi:10.1016/j.pain.2007.01.029
9. Turk DC, Okifuji A. Psychological factors in chronic pain: Evolution and revolution. Journal of Consulting and Clinical Psychology. 2002;70(3):678–90. doi:10.1037/0022-006x.70.3.678
10. Marchesi N, Govoni S, Allegri M. Non?drug pain relievers active on non?opioid pain mechanisms. Pain Practice. 2021;22(2):255–75. doi:10.1111/papr.13073
11. Bergman JE, Casiano RR, Perez AB, Mantero AM, Levine CG. Opiate vs non-opiate prescription medication for pain control after endoscopic sinus surgery for chronic rhinosinusitis. American Journal of Otolaryngology. 2022;43(1):103214. doi:10.1016/j.amjoto.2021.103214
12. Elphinston RA, Sullivan MJL, Sterling M, Connor JP, Baranoff JA, Tan D, et al. Pain medication beliefs mediate the relationship between pain catastrophizing and opioid prescription use in patients with chronic non-cancer pain. The Journal of Pain. 2022;23(3):379–89. doi:10.1016/j.jpain.2021.08.009
13. Nichols VP, Toye F, Eldabe S, Sandhu HK, Underwood M, Seers K. Experiences of people taking opioid medication for chronic non-malignant pain: A qualitative evidence synthesis using meta-ethnography. BMJ Open. 2020;10(2). doi:10.1136/bmjopen-2019-032988
14.  Pope JE, Deer TR. Opioids for chronic non-cancer pain. Deer’s Treatment of Pain. 2019;231–2. doi:10.1007/978-3-030-12281-2_28
15.   Migliorini F, Maffulli N, Eschweiler J, Tingart M, Baroncini A. Non-steroidal anti-inflammatory drugs and gabapentinoids for chronic lumbar pain: A bayesian network meta-analysis of randomized controlled trials. British Medical Bulletin. 2021;138(1):85–95. doi:10.1093/bmb/ldab003
16.  Hladkykh F. Multimodal analgesia: Polypharmacy in pain relief or rational use of non-steroidal anti-inflammatory drugs to prevent pain chronicity. Path of Science. 2020;6(7):4008–18. doi:10.22178/pos.60-5
17. Machado GC, Abdel-Shaheed C, Underwood M, Day RO. Non-steroidal anti-inflammatory drugs (nsaids) for musculoskeletal pain. BMJ. 2021; doi:10.1136/bmj.n104
18. Dara P, Talabi O, Iderapalli M. Non-steroidal anti-inflammatory drugs can interact with lithium and antidepressants. BMJ. 2021; doi:10.1136/bmj.n679
19. Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, et al. Antidepressants for pain management in adults with chronic pain: A network meta-analysis. Cochrane Database of Systematic Reviews. 2021; doi:10.1002/14651858.cd014682
20.  Kmietowicz Z. Offer exercise, therapy, acupuncture, or antidepressants for chronic primary pain, says nice. BMJ. 2021; doi:10.1136/bmj.n907
21. Brown M. New nice guideline: Antidepressants and chronic pain — chicken or egg? British Journal of General Practice. 2021;71(708):320–320. doi:10.3399/bjgp21x716345
22. Scherf-Clavel M, Breisinger S, Fischer M, Deckert J, Unterecker S, Rittner HL. Therapeutic drug monitoring of antidepressants for the treatment of chronic musculoskeletal pain with and without depression. Therapeutic Drug Monitoring. 2020;42(6):893–901. doi:10.1097/ftd.0000000000000783
23.  Ilmanita D, Hidayati HB. Tricyclic antidepressants in chronic low back pain?: A Review. Journal of Islamic Pharmacy. 2020;4(2):21. doi:10.18860/jip.v4i2.8217
24. Li CT, Watson JC. Anticonvulsants in the treatment of pain. Deer’s Treatment of Pain. 2019;149–61. doi:10.1007/978-3-030-12281-2_19
25. Javed S, Abdi S. Use of anticonvulsants and antidepressants for treatment of complex regional pain syndrome: A literature review. Pain Management. 2021;11(2):189–99. doi:10.2217/pmt-2020-0060
26. Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: A systematic review and meta-analysis. Canadian Medical Association Journal. 2018;190(26). doi:10.1503/cmaj.171333
27. Okafor C, Aquino M. Antidepressants and anticonvulsants. Academic Pain Medicine. 2019;75–9. doi:10.1007/978-3-030-18005-8_14
28. Shanthanna H, Busse J, Wang L, Kaushal A, Harsha P, Suzumura EA, et al. Addition of corticosteroids to local anaesthetics for chronic non-cancer pain injections: A systematic review and meta-analysis of Randomised Controlled Trials. British Journal of Anaesthesia. 2020;125(5):779–801. doi:10.1016/j.bja.2020.06.062
29.  Sheppard HN, Anandampillai R. Systemic toxic effects of local anaesthetics. Anaesthesia & Intensive Care Medicine. 2019;20(4):215–8. doi:10.1016/j.mpaic.2019.01.022
30. Chang WJ. Muscle relaxants for acute and chronic pain. Physical Medicine and Rehabilitation Clinics of North America. 2020;31(2):245–54. doi:10.1016/j.pmr.2020.01.005
31.  Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2011; doi:10.1002/14651858.cd008922
32.  Travnicek KD. Antispasmodics and muscle relaxants. Deer’s Treatment of Pain. 2019;181–9. doi:10.1007/978-3-030-12281-2_22
33. Oldfield BJ, Fuller WS, Becker WC. Opioids are not better than non-opioid pain medications for chronic back, hip, or knee pain. Journal of General Internal Medicine. 2019;34(9):1854–6. doi:10.1007/s11606-019-05016-4
34.  Dekeseredy P, Sedney CL, Razzaq B, Haggerty T, Brownstein HH. Tweeting stigma: An exploration of Twitter discourse regarding medications used for both opioid use disorder and chronic pain. Journal of Drug Issues. 2021;51(2):340–57. doi:10.1177/0022042620986508
35.  Phillips C, Contreras E, Oswald J. NSAIDs, opioids, and beyond. Pain Management - Practices, Novel Therapies and Bioactives. 2021; doi:10.5772/intechopen.93843
36.  Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. Journal of the Neurological Sciences. 2020;411:116728. doi:10.1016/j.jns.2020.116728
37. Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. Journal of the Neurological Sciences. 2020;411:116728. doi:10.1016/j.jns.2020.116728
38.  Asmar A. Psychotropic medications for chronic pain. Current Psychiatry. 2022;21(11). doi:10.12788/cp.0304
39. Vázquez M, Fagiolino P. Pharmacotherapy of chronic pain. Pain Relief - From Analgesics to Alternative Therapies. 2017; doi:10.5772/66444
40.  Koppert W. Opioid-induzierte hyperalgesie. Der Anaesthesist. 2004;53(5):455–66. doi:10.1007/s00101-004-0669-1
41. Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, et al. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology. 2017;116:59–70. doi:10.1016/j.neuropharm.2016.12.008
42.  Ma M, Li X, Tong K, Cheng J, Yu Z, Ren F, et al. Discovery of biased mu?opioid receptor agonists for the treatment of pain. ChemMedChem. 2019;15(1):155–61. doi:10.1002/cmdc.201900575
43.  Berthiaume S, Abdallah K, Blais V, Gendron L. Alleviating pain with Delta opioid receptor agonists: Evidence from experimental models. Journal of Neural Transmission. 2020;127(4):661–72. doi:10.1007/s00702-020-02172-4
44. Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, et al. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology. 2017;116:59–70. doi:10.1016/j.neuropharm.2016.12.008
45.  Salvemini D, Jacobson KA. Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opinion on Therapeutic Patents. 2017;27(8):967–967. doi:10.1080/13543776.2017.1341018
46. Ma M, Li X Tong K, Cheng J, Yu Z, Ren F, et al. Discovery of biased mu?opioid receptor agonists for the treatment of pain. ChemMedChem. 2019;15(1):155–61. doi:10.1002/cmdc.201900575
47. Berthiaume S, Abdallah K, Blais V, Gendron L. Alleviating pain with Delta opioid receptor agonists: Evidence from experimental models. Journal of Neural Transmission. 2020;127(4):661–72. doi:10.1007/s00702-020-02172-4
48. Starnowska-Sokó? J, Piotrowska A, Bogacka J, Makuch W, Mika J, Witkowska E, et al. Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of Neuropathic Pain. Neuropharmacology. 2020;178:108232. doi:10.1016/j.neuropharm.2020.108232
49. J. Urtisky, PharmD, BCPS, CPE T. Methylnaltrexone: Peripherally acting ?-opioid receptor antagonist. Journal of the Advanced Practitioner in Oncology. 2019;10(1). doi:10.6004/jadpro.2019.10.1.5
50.  Turnaturi R, Chiechio S, Pasquinucci L, Spoto S, Costanzo G, Dichiara M, et al. Novel N-normetazocine derivatives with opioid agonist/sigma-1 receptor antagonist profile as potential analgesics in inflammatory pain. Molecules. 2022;27(16):5135. doi:10.3390/molecules27165135
51. Hasvik E, Gran JM, Haugen AJ, Grøvle L. Strategies to manage auxiliary pain medications in chronic pain trials: A topical review. European Journal of Clinical Pharmacology. 2022;78(9):1377–84. doi:10.1007/s00228-022-03355-6
52.  Urits I, Li N, Berardino K, Artounian KA, Bandi P, Jung JW, et al. The use of antineuropathic medications for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):493–506. doi:10.1016/j.bpa.2020.08.007
53.  Shen Y, Hincapie-Castillo J, Vouri S, Dewar M, Sumfest J, Goodin A. Prescription patterns of adjuvant pain medications following an opioid supply restriction law. Medical Care. 2022;60(6):432–6. doi:10.1097/mlr.0000000000001719
54. Rivasi G, Menale S, Turrin G, Coscarelli A, Giordano A, Ungar A. The effects of pain and analgesic medications on blood pressure. Current Hypertension Reports. 2022;24(10):385–94. doi:10.1007/s11906-022-01205-5
55. Shanthanna H, Busse J, Wang L, Kaushal A, Harsha P, Suzumura EA, et al. Addition of corticosteroids to local anaesthetics for chronic non-cancer pain injections: A systematic review and meta-analysis of Randomised Controlled Trials. British Journal of Anaesthesia. 2020;125(5):779–801. doi:10.1016/j.bja.2020.06.062
56. Knezevic NN, Jovanovic F, Voronov D, Candido KD. Do corticosteroids still have a place in the treatment of chronic pain? Frontiers in Pharmacology. 2018;9. doi:10.3389/fphar.2018.01229
57. Fabregat C, Almendros S, Navarro?Martin A, Gonzalez J. Pain flare?effect prophylaxis with corticosteroids on bone radiotherapy treatment: A systematic review. Pain Practice. 2019;20(1):101–9. doi:10.1111/papr.12823
58. Clayburgh D, Stott W, Bolognone R, Palmer A, Achim V, Troob S, et al. A randomized controlled trial of corticosteroids for pain after transoral robotic surgery. The Laryngoscope. 2017;127(11):2558–64. doi:10.1002/lary.26625
59. Ferraro MC, Cashin AG, O’Connell NE, Visser EJ, Abdel Shaheed C, Wewege MA, et al. Ketamine and other NMDA receptor antagonists for chronic pain. Cochrane Database of Systematic Reviews. 2023;2023(3). doi:10.1002/14651858.cd015373
60.  Kreutzwiser D, Tawfic QA. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs. 2019;33(4):347–74. doi:10.1007/s40263-019-00618-2
61.  Kamdar MM. Ketamine and NMDA-receptor antagonists. Deer’s Treatment of Pain. 2019;199–204. doi:10.1007/978-3-030-12281-2_24
62.  Schroeder C, Schroeder K. NMDA receptor antagonists. Pain. 2019;285–7. doi:10.1007/978-3-319-99124-5_62
63. Peppin JF, Wright SL. Benzodiazepines and pain management. The Benzodiazepines Crisis. 2020;149–59. doi:10.1093/med/9780197517277.003.0009
64. Wright SL. Limited utility for benzodiazepines in Chronic pain management: A narrative review. Advances in Therapy. 2020;37(6):2604–19. doi:10.1007/s12325-020-01354-6
65. Gauntlett-Gilbert J, Gavriloff D, Brook P. Benzodiazepines may be worse than opioids. The Clinical Journal of Pain. 2016;32(4):285–91. doi:10.1097/ajp.0000000000000253
66.  Zaman T, Rife TL, Batki SL, Pennington DL. An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines. Substance Abuse. 2018;39(4):441–8. doi:10.1080/08897077.2018.1455163
67. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of Randomized Trials. British Journal of Clinical Pharmacology. 2011;72(5):735–44. doi:10.1111/j.1365-2125.2011.03970.x
68. Lynch ME. Cannabinoids in the management of chronic pain: A Front Line Clinical Perspective. Journal of Basic and Clinical Physiology and Pharmacology. 2015;27(3):189–91. doi:10.1515/jbcpp-2015-0059
69. Ma X, Zhou S, Sun W, Sun J, Li G, Wang L, et al. Efficacy and safety of duloxetine in chronic musculoskeletal pain: A systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2023;24(1). doi:10.1186/s12891-023-06488-6
70. Villanueva MR, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, et al. Efficacy, safety, and regulation of Cannabidiol on Chronic Pain: A systematic review. Cureus. 2022; doi:10.7759/cureus.26913
71. Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, et al. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: A systematic review and meta-analyses. Pain. 2021;163(4):610–36. doi:10.1097/j.pain.0000000000002423
72.  van de Kooij P. Comments on the efficacy and safety of opioidanalgesics for the management of chronic lowback pain. Pain Physician. 2021; doi:10.36076/ppj.2021/24/e377
73. Mekhail N, Eldabe S, Templeton E, Costandi S, Rosenquist R. Pain management interventions for the treatment of chronic low back pain. The Clinical Journal of Pain. 2023;39(7):349–64. doi:10.1097/ajp.0000000000001116
74. Tucker-Bartley A, Selen DJ, Golden E, van Gool R, Ebb D, Mannstadt M, et al. Pharmacological interventions targeting pain in fibrous dysplasia/McCune–Albright syndrome. International Journal of Molecular Sciences. 2023;24(3):2550. doi:10.3390/ijms24032550
75. Davies A. Interventional Pain Management and chronic low back pain: Effectiveness and patient outcomes. American Journal of Biomedical Science & Research. 2022;15(5):575–80. doi:10.34297/ajbsr.2022.15.002156
76. Schemer L, Rief W, Glombiewski JA.

    treatment expectations towards different pain management approaches: Two perspectives

    . Journal of Pain Research. 2020;Volume 13:1725–36. doi:10.2147/jpr.s247177
77.  Petelin DS, Istomina NS, Tsapko DS, Magomedov AA, Bezrukov VE, Kochergina MS, et al. Approaches to psychotherapy for chronic musculoskeletal pain. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):68–73. doi:10.14412/2074-2711-2022-3-68-73
78. Smith TE. Interventional treatment of chronic pain. Chronic Pain Management in General and Hospital Practice. 2020;113–28. doi:10.1007/978-981-15-2933-7_7
79.  Cheville AL, Basford JR. Rehabilitation medicine approaches to pain management. Oxford Textbook of Palliative Medicine. 2015;606–13. doi:10.1093/med/9780199656097.003.0910
80. Aravagiri K, Ali A, Wang HC, Candido KD, Knezevic NN. Identifying molecular mechanisms of acute to chronic pain transition and potential drug targets. Expert Opinion on Therapeutic Targets. 2022;26(9):801–10. doi:10.1080/14728222.2022.2137404
81. Bernatoniene J, Sciupokas A, Kopustinskiene DM, Petrikonis K. Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics. 2023;15(7):1799. doi:10.3390/pharmaceutics15071799
82. Obeng S, Hiranita T, León F, McMahon LR, McCurdy CR. Novel approaches, drug candidates, and targets in Pain drug discovery. Journal of Medicinal Chemistry. 2021;64(10):6523–48. doi:10.1021/acs.jmedchem.1c00028
83. Sisignano M, Parnham MJ, Geisslinger G. Novel approaches to persistent pain therapy. Trends in Pharmacological Sciences. 2019;40(6):367–77. doi:10.1016/j.tips.2019.04.003
84. Auyeung A, Wang HC, Aravagiri K, Knezevic NN. Kynurenine pathway metabolites as potential biomarkers in chronic pain. Pharmaceuticals. 2023;16(5):681. doi:10.3390/ph16050681
85.  Eldabe S, Obara I, Panwar C, Caraway D. Biomarkers for chronic pain: Significance and summary of recent advances. Pain Research and Management. 2022;2022:1–6. doi:10.1155/2022/1940906
86.  Morales AG, Lee JJ, Caliva F, Iriondo C, Liu F, Majumdar S, et al. Uncovering associations between data-driven learned QMRI biomarkers and chronic pain. Scientific Reports. 2021;11(1). doi:10.1038/s41598-021-01111-x
87. Zhang Z, Gewandter JS, Geha P. Brain imaging biomarkers for chronic pain. Frontiers in Neurology. 2022;12. doi:10.3389/fneur.2021.734821
88. Karimian F, Saadat S, Hosseininezhad M. Chronic pain and psychological interventions: A systematic review. Iranian Journal of Neurosurgery. 2023;9(0):6–6. doi:10.32598/irjns.9.8
89. Morris JR, Harrison SL, Robinson J, Martin D, Avery L. Non-pharmacological and non-invasive interventions for chronic pain in people with chronic obstructive pulmonary disease: A systematic review without meta-analysis. Respiratory Medicine. 2023;211:107191. doi:10.1016/j.rmed.2023.107191
90. Mekhail N, Eldabe S, Templeton E, Costandi S, Rosenquist R. Pain management interventions for the treatment of chronic low back pain. The Clinical Journal of Pain. 2023;39(7):349–64. doi:10.1097/ajp.0000000000001116
91.  Peters M. Can perioperative psychological interventions reduce chronic pain after surgery? British Journal of Hospital Medicine. 2023;84(5):1–8. doi:10.12968/hmed.2022.0400